Loading...
  • gene
  • Human dipeptidyl peptidase IV gene promoter: tissue-specific regulation from a TATA-less GC-rich sequence characteristic of a housekeeping gene promoter. (springer.com)
  • Active and inactive (or total) incretin plasma concentrations, plasma DPP-4 activity, and preproglucagon (GCG) gene expression were determined after administration of each agent alone or in combination to mice with diet-induced obesity (DIO) and to healthy human subjects. (nih.gov)
  • hypoxia
  • Shedding of dipeptidyl peptidase 4 is mediated by metalloproteases and up-regulated by hypoxia in human adipocytes and smooth muscle cells. (springer.com)
  • B. H. Jiang, G. L. Semenza, C. Bauer, and H. H. Marti, "Hypoxia-inducible factor 1 levels vary exponentially over a physiologically relevant range of O2 tension," American Journal of Physiology , vol. 271, no. 4, pp. (hindawi.com)
  • incretin
  • The aim of the study was to investigate the effects of a dipeptidyl peptidase-4 (DPP-4) inhibitor, of metformin, and of the combination of the two agents, on incretin hormone concentrations. (nih.gov)
  • While the clinical benefit of incretin-based drugs has been proven for controlling blood glucose level ( 1 - 3 ), there have been concerns about an increased risk of acute pancreatitis ( 4 , 5 ). (diabetesjournals.org)
  • physiological
  • Among other physiological substrates of DPP-4 is stromal-derived factor-1α (SDF-1α) ( 6 ), a chemokine that stimulates bone marrow mobilization of EPCs ( 7 ). (diabetesjournals.org)
  • EXAMINE
  • We aimed to examine the effects of vildagliptin, a specific DPP-4 inhibitor, on blood pressure and its dipping pattern in Dahl salt-sensitive (DSS) rats. (ahajournals.org)
  • Patients
  • Background Although recent clinical trials raised concerns about the risk for heart failure (HF) in dipeptidyl peptidase-4 (DPP-4) inhibitor use, data on the cardiovascular risks in the patients with pre-existing HF are still lacking. (bmj.com)
  • DPP-4 inhibitor use was not associated with a higher risk of hospitalisation for HF even in patients with pre-existing HF. (bmj.com)
  • Plasma dipeptidyl-peptidase-4 activity is associated with left ventricular systolic function in patients with ST-segment elevation myocardial infarction. (physiciansweekly.com)
  • receptor
  • Thirdly, GLP-1 receptor mutation or other defect in β-cell responsiveness to GLP-1 leads to reduction of response to DPP-4 inhibitor. (clinicaltrials.gov)
  • rats
  • Phenotyping of congenic dipeptidyl peptidase 4 (DP4) deficient Dark Agouti (DA) rats suggests involvement of DP4 in neuro-, endocrine, and immune functions. (springer.com)
  • In anesthetized high salt-diet DSS rats, acute intra-cerebroventricular infusion of vildagliptin (50, 500 or 2500 μg in 10 μl solution) did not alter MAP or heart rate (n = 4). (ahajournals.org)
  • Human
  • Crystal structure of human dipeptidyl peptidase IV in complex with a decapeptide reveals details on substrate specificity and tetrahedral intermediate formation. (springer.com)
  • Some studies describe the existence of human DPP-4 homologs in commensal bacteria, for instance in Prevotella or Lactobacillus . (frontiersin.org)
  • Effects
  • Since few head-to-head trials have compared the effects of different oral glucose-lowering agents on CV outcomes in T2DM, with most CVOTs using placebo as a comparator, the CAROLINA trial will provide important information on the comparative CV safety of a commonly prescribed SU and a DPP-4 inhibitor. (springer.com)